6-溴-3H-恶唑并[4,5-b]吡啶-2-酮 | 21594-52-5

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 中文名称: 6-溴-3H-恶唑并[4,5-b]吡啶-2-酮
• 中文别名: 6-溴-3H-恶唑并[4,5-B]吡啶-2-酮；6-溴-2,3-二氢吡啶并[2,3-D][1,3]唑-2-酮；6-溴-2H,3H-[1,3]噁唑并[4,5-b]吡啶-2-酮
• 英文名称: 6-bromo-3H-oxazolo[4,5-b]pyridin-2-one
• 英文别名: 6-bromooxazolo[4,5-b]pyridin-2(3H)-one；6-bromooxazolo<4,5-b>pyridin-2(3H)-one；6-bromo[1,3]oxazolo[4,5-b]pyridin-2(3H)-one；6-bromooxazolo[4,5-b]pyridine-2(3H)-one；6-Brom-oxazolo<4,5-b>pyridin-2(3H)on；6-bromo-3H-[1,3]oxazolo[4,5-b]pyridin-2-one
• CAS: 21594-52-5
• 化学式: C₆H₃BrN₂O₂
• mdl: MFCD08689590
• 分子量: 215.006
• InChiKey: VQPBRWIFFBIRRP-UHFFFAOYSA-N

物化性质

• 熔点：
  233-235 °C
• 沸点：
  219.7±50.0 °C(Predicted)
• 密度：
  2.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-3H-oxazolo[4,5-b]pyridin-2-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-3H-oxazolo[4,5-b]pyridin-2-one
CAS number: 21594-52-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3BrN2O2
Molecular weight: 215.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

医药中间体。

用途简介

反应信息

• 作为反应物：
  描述：

  6-溴-3H-恶唑并[4,5-b]吡啶-2-酮 在 sodium hydroxide 、 六甲基二硅氧烷 、 phosphorus pentoxide 作用下， 以 水 为溶剂， 反应 13.0h， 生成 6-溴-2-苯基恶唑并[4,5-B]吡啶
  参考文献：
  名称：

  Viaud, Marie-Claude; Jamoneau, Patricia; Savelon, Laurence, Heterocycles, 1995, vol. 41, # 12, p. 2799 - 2810

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(3-羟基吡啶-2-基)氨基甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二苯醚 、 乙腈 为溶剂， 反应 5.0h， 生成 6-溴-3H-恶唑并[4,5-b]吡啶-2-酮
  参考文献：
  名称：

  [EN] PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS
  [FR] DÉRIVÉS DE PYRIMIDINE ET DE TRIAZINE, ET LEUR UTILISATION COMME INHIBITEURS D'AXL

  摘要：

  公式(I)的化合物： (I) 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。

  公开号：

  WO2016097918A1

文献信息

• Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
  申请人：Cui Jean Jingrong

  公开号：US20060046991A1

  公开（公告）日：2006-03-02

  Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

  提供了式1的对映纯化合物，以及它们的合成和使用方法。优选化合物是c-Met蛋白激酶的强效抑制剂，并且在治疗异常细胞生长紊乱，如癌症方面具有用处。
• HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS
  申请人：VITAS PHARMA RESEARCH PRIVATE LIMITED

  公开号：US20140249170A1

  公开（公告）日：2014-09-04

  The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.

  这项发明涉及一种新型杂环化合物，可以特异性地抑制细菌FabI，并可用于治疗葡萄球菌感染。
• IMIDAZOPYRAZINES AS LSD1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20160009720A1

  公开（公告）日：2016-01-14

  The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及咪唑并[1,2-a]吡嗪衍生物，这些衍生物是LSD1抑制剂，可用于治疗癌症等疾病。
• [EN] BIARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS BIARYLES ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：AMBIT BIOSCIENCES CORP

  公开号：WO2011022473A1

  公开（公告）日：2011-02-24

  Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗KIT、CSF-1R和/或FLT3激酶介导疾病的化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• PDE4 INHIBITOR
  申请人：SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.

  公开号：US20190177318A1

  公开（公告）日：2019-06-13

  Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

  提供了一种PDE4抑制剂及其在制备用于治疗与PDE4相关疾病的药物中的用途。具体披露了如公式（I）所示的化合物及其药用可接受的盐。